Efgivanermin alfa

依瓦奈明α

Report date: 2023/12/19 20:05:05

Base Information

Drug NameEfgivanermin alfa
Drug Alias NameMEDI-1873
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionImmunomodulatorsGlucocorticoid-induced tumor necrosis factor receptor-related protein agonists
TargetsGlucocorticoid-induced tumor necrosis factor receptor-related protein
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedimmune
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedimmune Llc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A